The promise of the gut microbiome as part of individualized treatment strategies
Daniel A. Schupack, Ruben A.T. Mars, Dayne H. Voelker, Jithma P. Abeykoon, Purna C. Kashyap
Variability in disease presentation, progression and treatment response has been a central challenge in medicine. Although variability in host factors and genetics are important, it has become evident that the gut microbiome, with its vast genetic and metabolic diversity, must be considered in moving towards individualized treatment. In this Review, we discuss six broad disease groups: infectious disease, cancer, metabolic disease, cardiovascular disease, autoimmune or inflammatory disease, and allergic and atopic diseases. We highlight current knowledge on the gut microbiome in disease pathogenesis and prognosis, efficacy, and treatment-related adverse events and its promise for stratifying existing treatments and as a source of novel therapies. The Review is not meant to be comprehensive for each disease state but rather highlights the potential implications of the microbiome as a tool to individualize treatment strategies in clinical practice. Although early, the outlook is optimistic but challenges need to be overcome before clinical implementation, including improved understanding of underlying mechanisms, longitudinal studies with multiple data layers reflecting gut microbiome and host response, standardized approaches to testing and reporting, and validation in larger cohorts. Given progress in the microbiome field with concurrent basic and clinical studies, the microbiome will likely become an integral part of clinical care within the next decade.
Nature Reviews Gastroenterology and Hepatology
Dive into the research topics of 'The promise of the gut microbiome as part of individualized treatment strategies'. Together they form a unique fingerprint.
Gastrointestinal Microbiome Medicine & Life Sciences 100%
Metabolic Diseases Medicine & Life Sciences 21%
Genetic Variation Medicine & Life Sciences 19%
Autoimmune Diseases Medicine & Life Sciences 17%
Communicable Diseases Medicine & Life Sciences 17%
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022). The promise of the gut microbiome as part of individualized treatment strategies. Nature Reviews Gastroenterology and Hepatology, 19(1), 7-25. https://doi.org/10.1038/s41575-021-00499-1
The promise of the gut microbiome as part of individualized treatment strategies. / Schupack, Daniel A.; Mars, Ruben A.T.; Voelker, Dayne H.; Abeykoon, Jithma P.; Kashyap, Purna C.
In: Nature Reviews Gastroenterology and Hepatology, Vol. 19, No. 1, 01.2022, p. 7-25.
Schupack, DA, Mars, RAT, Voelker, DH, Abeykoon, JP & Kashyap, PC 2022, 'The promise of the gut microbiome as part of individualized treatment strategies', Nature Reviews Gastroenterology and Hepatology, vol. 19, no. 1, pp. 7-25. https://doi.org/10.1038/s41575-021-00499-1
Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nature Reviews Gastroenterology and Hepatology. 2022 Jan;19(1):7-25. https://doi.org/10.1038/s41575-021-00499-1
Schupack, Daniel A. ; Mars, Ruben A.T. ; Voelker, Dayne H. ; Abeykoon, Jithma P. ; Kashyap, Purna C. / The promise of the gut microbiome as part of individualized treatment strategies. In: Nature Reviews Gastroenterology and Hepatology. 2022 ; Vol. 19, No. 1. pp. 7-25.
@article{8619116df5a94a63b940997986523f02,
title = "The promise of the gut microbiome as part of individualized treatment strategies",
abstract = "Variability in disease presentation, progression and treatment response has been a central challenge in medicine. Although variability in host factors and genetics are important, it has become evident that the gut microbiome, with its vast genetic and metabolic diversity, must be considered in moving towards individualized treatment. In this Review, we discuss six broad disease groups: infectious disease, cancer, metabolic disease, cardiovascular disease, autoimmune or inflammatory disease, and allergic and atopic diseases. We highlight current knowledge on the gut microbiome in disease pathogenesis and prognosis, efficacy, and treatment-related adverse events and its promise for stratifying existing treatments and as a source of novel therapies. The Review is not meant to be comprehensive for each disease state but rather highlights the potential implications of the microbiome as a tool to individualize treatment strategies in clinical practice. Although early, the outlook is optimistic but challenges need to be overcome before clinical implementation, including improved understanding of underlying mechanisms, longitudinal studies with multiple data layers reflecting gut microbiome and host response, standardized approaches to testing and reporting, and validation in larger cohorts. Given progress in the microbiome field with concurrent basic and clinical studies, the microbiome will likely become an integral part of clinical care within the next decade.",
author = "Schupack, {Daniel A.} and Mars, {Ruben A.T.} and Voelker, {Dayne H.} and Abeykoon, {Jithma P.} and Kashyap, {Purna C.}",
note = "Funding Information: The authors thank L. Busby for her secretarial assistance. This work is supported by funding from NIH DK114007, Center for Individualized Medicine and Department of Medicine Mayo Clinic, Rochester, MN, USA. Publisher Copyright: {\textcopyright} 2021, Springer Nature Limited.",
journal = "Nature Reviews Gastroenterology and Hepatology",
T1 - The promise of the gut microbiome as part of individualized treatment strategies
AU - Schupack, Daniel A.
AU - Mars, Ruben A.T.
AU - Voelker, Dayne H.
AU - Abeykoon, Jithma P.
AU - Kashyap, Purna C.
N1 - Funding Information: The authors thank L. Busby for her secretarial assistance. This work is supported by funding from NIH DK114007, Center for Individualized Medicine and Department of Medicine Mayo Clinic, Rochester, MN, USA. Publisher Copyright: © 2021, Springer Nature Limited.
N2 - Variability in disease presentation, progression and treatment response has been a central challenge in medicine. Although variability in host factors and genetics are important, it has become evident that the gut microbiome, with its vast genetic and metabolic diversity, must be considered in moving towards individualized treatment. In this Review, we discuss six broad disease groups: infectious disease, cancer, metabolic disease, cardiovascular disease, autoimmune or inflammatory disease, and allergic and atopic diseases. We highlight current knowledge on the gut microbiome in disease pathogenesis and prognosis, efficacy, and treatment-related adverse events and its promise for stratifying existing treatments and as a source of novel therapies. The Review is not meant to be comprehensive for each disease state but rather highlights the potential implications of the microbiome as a tool to individualize treatment strategies in clinical practice. Although early, the outlook is optimistic but challenges need to be overcome before clinical implementation, including improved understanding of underlying mechanisms, longitudinal studies with multiple data layers reflecting gut microbiome and host response, standardized approaches to testing and reporting, and validation in larger cohorts. Given progress in the microbiome field with concurrent basic and clinical studies, the microbiome will likely become an integral part of clinical care within the next decade.
AB - Variability in disease presentation, progression and treatment response has been a central challenge in medicine. Although variability in host factors and genetics are important, it has become evident that the gut microbiome, with its vast genetic and metabolic diversity, must be considered in moving towards individualized treatment. In this Review, we discuss six broad disease groups: infectious disease, cancer, metabolic disease, cardiovascular disease, autoimmune or inflammatory disease, and allergic and atopic diseases. We highlight current knowledge on the gut microbiome in disease pathogenesis and prognosis, efficacy, and treatment-related adverse events and its promise for stratifying existing treatments and as a source of novel therapies. The Review is not meant to be comprehensive for each disease state but rather highlights the potential implications of the microbiome as a tool to individualize treatment strategies in clinical practice. Although early, the outlook is optimistic but challenges need to be overcome before clinical implementation, including improved understanding of underlying mechanisms, longitudinal studies with multiple data layers reflecting gut microbiome and host response, standardized approaches to testing and reporting, and validation in larger cohorts. Given progress in the microbiome field with concurrent basic and clinical studies, the microbiome will likely become an integral part of clinical care within the next decade.
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology